Rugo HS - Search Results

1

Role of Fcγ receptors in HER2-targeted breast cancer therapy.

Musolino A, Gradishar WJ, Rugo HS, Nordstrom JL, Rock EP, Arnaldez F, Pegram MD. Musolino A, et al. Among authors: rugo hs. J Immunother Cancer. 2022 Jan;10(1):e003171. doi: 10.1136/jitc-2021-003171. J Immunother Cancer. 2022. PMID: 34992090 Free PMC article. Review.

2

Triple-negative breast cancer: role of antiangiogenic agents.

Greenberg S, Rugo HS. Greenberg S, et al. Among authors: rugo hs. Cancer J. 2010 Jan-Feb;16(1):33-8. doi: 10.1097/PPO.0b013e3181d38514. Cancer J. 2010. PMID: 20164688 Review.

3

The cardiac safety of trastuzumab in the treatment of breast cancer.

Chien AJ, Rugo HS. Chien AJ, et al. Among authors: rugo hs. Expert Opin Drug Saf. 2010 Mar;9(2):335-46. doi: 10.1517/14740331003627441. Expert Opin Drug Saf. 2010. PMID: 20175700 Review.

4

Challenging clinical scenarios: treatment of patients with triple-negative or basal-like metastatic breast cancer.

Greenberg S, Rugo HS. Greenberg S, et al. Among authors: rugo hs. Clin Breast Cancer. 2010 Sep;10 Suppl 2:S20-9. doi: 10.3816/CBC.2010.s.009. Clin Breast Cancer. 2010. PMID: 20805062 Review.

5

Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.

DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirström K, West BL, Coussens LM. DeNardo DG, et al. Among authors: rugo hs. Cancer Discov. 2011 Jun;1(1):54-67. doi: 10.1158/2159-8274.CD-10-0028. Epub 2011 Jun 1. Cancer Discov. 2011. PMID: 22039576 Free PMC article.

6

A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer.

Rugo HS, Chien AJ, Franco SX, Stopeck AT, Glencer A, Lahiri S, Arbushites MC, Scott J, Park JW, Hudis C, Nulsen B, Dickler MN. Rugo HS, et al. Breast Cancer Res Treat. 2012 Jul;134(1):13-20. doi: 10.1007/s10549-011-1918-z. Epub 2011 Dec 24. Breast Cancer Res Treat. 2012. PMID: 22198412 Free PMC article. Clinical Trial.

7

Neoadjuvant therapy for HER2-positive early-stage breast cancer: the future is almost here.

Rugo HS. Rugo HS. Oncology (Williston Park). 2012 Jan;26(1):26, 28-9. Oncology (Williston Park). 2012. PMID: 22393793 Free article. No abstract available.

8

The role of targeted therapy and biomarkers in breast cancer treatment.

Stopeck AT, Brown-Glaberman U, Wong HY, Park BH, Barnato SE, Gradishar WJ, Hudis CA, Rugo HS. Stopeck AT, et al. Among authors: rugo hs. Clin Exp Metastasis. 2012 Oct;29(7):807-19. doi: 10.1007/s10585-012-9496-y. Epub 2012 Jun 13. Clin Exp Metastasis. 2012. PMID: 22692561 Review.

9

Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients.

Magbanua MJ, Sosa EV, Roy R, Eisenbud LE, Scott JH, Olshen A, Pinkel D, Rugo HS, Park JW. Magbanua MJ, et al. Among authors: rugo hs. Cancer Res. 2013 Jan 1;73(1):30-40. doi: 10.1158/0008-5472.CAN-11-3017. Epub 2012 Nov 7. Cancer Res. 2013. PMID: 23135909 Free PMC article.

10

Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer.

Chien AJ, Rugo HS. Chien AJ, et al. Among authors: rugo hs. Breast Cancer Res Treat. 2013 Jan;137(1):1-12. doi: 10.1007/s10549-012-2328-6. Epub 2012 Nov 10. Breast Cancer Res Treat. 2013. PMID: 23143215 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

498 results

Search Page